{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-101298","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.920933+00:00","generated_at":"2026-06-23T08:25:57.351005+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD","bullets":["DSMC recommended termination after routine safety and efficacy analysis.","Study evaluated Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension with COPD.","Company will review available data and share results with the scientific community.","Tyvaso is already approved for PAH and PH-ILD; termination affects a potential label expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-101298","json":"https://secwatch.observer/filing/0001104659-22-101298.json","markdown":"https://secwatch.observer/filing/0001104659-22-101298.md","text":"https://secwatch.observer/filing/0001104659-22-101298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/0001104659-22-101298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922101298/tm2226246d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:25:57.351005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}